Greenwich LifeSciences (Greenwich LifeSciences) Total Current Liabilities : $0.39 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Greenwich LifeSciences's total current liabilities for the quarter that ended in Mar. 2024 was $0.39

Greenwich LifeSciences Total Current Liabilities Historical Data

The historical data trend for Greenwich LifeSciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Total Current Liabilities Chart

Greenwich LifeSciences Annual Data

Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 1.38 1.05 0.39 0.26 0.29

Greenwich LifeSciences Quarterly Data

Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24

Total Current Liabilities Get a 7-Day Free Trial 0.24 0.30 0.30 0.29 0.39

Greenwich LifeSciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Greenwich LifeSciences's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.294 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.29

Greenwich LifeSciences's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.39 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Greenwich LifeSciences Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Total Current Liabilities

Comparable Companies

IMAB PLX CDXS CYT SEER PROK MLEC AADI ABSI THRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

N/A

Address

3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website

https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.

Executives

Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479

Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380

Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479

Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479

David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816

Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479

Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477

Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530

Greenwich LifeSciences (Greenwich LifeSciences) Headlines

From GuruFocus

An Insider Just Bought Shares of Greenwich LifeSciences Inc; Could This Stock Be a Value Opportunity?
By GuruFocus Research GuruFocus Editor • 06-13-2022

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
By Business Wire Business Wire • 04-20-2022

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?
By GuruFocus Research GuruFocus Editor • 06-27-2022

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?
By GuruFocus Research GuruFocus Editor • 02-14-2023

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?
By GuruFocus Research GuruFocus Editor • 01-31-2023

Greenwich LifeSciences Announces Suspension of Share Repurchase Program
By Business Wire Business Wire • 07-11-2022

Insider Buying: Snehal Patel Acquires 1,000 Shares of Greenwich LifeSciences Inc
By GuruFocus Research • 09-13-2023

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
By Business Wire Business Wire • 08-03-2022

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
By Business Wire Business Wire • 12-08-2021

Greenwich LifeSciences Provides Financing Strategy & Corporate Update
By Business Wire Business Wire • 07-28-2022

Greenwich LifeSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Liabilities	Get a 7-Day Free Trial															0.24	0.30	0.30	0.29	0.39

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	0.294	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	0
	=	0.29

Snehal Patel	director, officer: CHIEF EXECUTIVE OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson	officer: VPC AND REGULATORY AFFAIRS	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty	director, officer: CHIEF MEDICAL OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams	director	2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel	10 percent owner	3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel	10 percent owner	50726 LAKESIDE DRIVE, GRANGER IN 46530